ClinicalTrials.gg
RecruitingNCT07155226MOMENTUMUpdated Oct 23, 2026

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

A Phase 1/2 interventional study of AZD3632 and Posaconazole in Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia and Higher-risk Myelodysplastic Syndromes, sponsored by AstraZeneca. Recruiting at 30 sites in 9 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Oct 23, 2026Site recruiting status changedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
85
Allocation
Non-randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States — 171 open to participants now, 277 under way, 13 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States.

Planned enrollment
251st of 1,269
85 · median 35
Started
2026
with 38 others
Phase 1/2
153 of 1,545
17 open now
Primary completion
2029-02
later than 221 of 275 live
Registered
1,507th of 1,545
by date

Among the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, this one is the 251st largest by planned enrollment of the 1,269 interventional ones that give a count, is one of 39 that started in 2026, is one of 153 in phase 1/2, reaches primary completion later than 221 of the 275 other live ones, and was the 1,507th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 474 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

171 of the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States are open now. Recruiting first, the newest first:

166 more — sign in →

All 171 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 371 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 258 (70%) stop at 75 or younger; 248 take children under 18; 29 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to understand the safety, tolerability, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of orally administered AZD3632 in participants with advanced haematologic malignancies with KMT2Ar, NPM1m, or other genotypes associated with homeobox (HOX) overexpression.

Read the detailed description

This is a first in human (FTiH), open-label, multi-centre study of AZD3632 in participants with relapsed or refractory acute leukaemia or myelodysplastic Syndromes (MDS) with HOX overexpression genotypes.

This study includes multiple modules (module 1 and module 2) each investigating AZD3632 in a specific population and/or in combination with other anticancer agents.

Module 1 is a dose escalation of AZD3632 monotherapy. Module 2 will investigate the safety, PK, and tolerability when co-administered with posaconazole.

03

Conditions studied

  • Acute Lymphoblastic Leukaemia
  • Acute Myeloid Leukaemia
  • Higher-risk Myelodysplastic Syndromes

Keywords

  • Myelodysplastic Syndromes
  • Menin inhibitor
  • Anti-leukaemic activity
  • Anti-fungal agent
  • HOX overexpression.
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

Core criteria:

  • Adequate organ function.
  • use by participants or participant partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Module 1:

  • Advanced haematologic - a) for dose escalation - diagnosis of acute leukemia or myelodysplastic neoplasia (MDS) and harbouring one of the genetic alterations per local testing associated with upregulation of HOX; b) for Backfill - diagnosis of harbouring a KMT2Ar or NPM1m per local testing.
  • Participants must have that is to conventional therapies known to be effective for their disease and not have any available approved therapies.: a) Relapsed and primary refractory acute leukaemia after standard of care therapy including but not limited to 2 cycles of intensive chemotherapy, hypomethylating agent (HMA) monotherapy, or HMA combinations such as HMA/venetoclax.; b) Relapsed and primary refractory MDS is defined by ≥ 5% blasts in the bone marrow and/or persistence of peripheral blasts after treatment with at least 2 cycles of HMA. Participants ineligible for the treatment with an HMA and without any other standard of care (SoC) options are allowed to enrol; c) White blood cell count below 25,000/μL. Participants may receive cytoreduction per protocol-specified criteria; d) Performance status: Eastern Cooperative Operative Group () ≤ 2; e) : ≥ 8 weeks.

Module 2:

  • Participants must have measurable disease that is relapsed/refractory to conventional therapies known to be effective for their disease and not have any available approved therapies.: a) Relapsed and primary refractory acute leukaemia after standard of care therapy including but not limited to 2 cycles of intensive chemotherapy, HMA monotherapy, or HMA combinations such as HMA/venetoclax.; b) Relapsed and primary refractory MDS is defined by ≥ 5% blasts in the bone marrow and/or persistence of peripheral blasts after treatment with at least 2 cycles of HMA. Participants ineligible for the treatment with an HMA and without any other SoC options are allowed to enrol; c) White blood cell count below 25,000/μL. Participants may receive cytoreduction per protocol-specified criteria; d) Performance status: ECOG ≤ 2; e) Life expectancy: ≥ 8 weeks.

Key Exclusion Criteria:

Core criteria:

  • Participants with Burkitt lymphoma/leukaemia or Acute Promyelocytic Leukaemia.
  • Active testicular or active central nervous system (CNS) (> CNS1 or radiographic) involvement by leukaemia.
  • Unresolved treatment-related toxicities Grade ≥ 2 from prior therapy.
  • Abnormal levels of potassium or magnesium prior to first dose of AZD3632.

Module 1:

  • Receipt of non-CNS radiation therapy within 2 weeks and of CNS radiation within 8 weeks of the first scheduled dose.
  • Receipt of any or non-investigational anticancer agents, including non-biologic agents, biologic agents and/or prior treatment other menin inhibitors (backfill participants only).
  • For nested food effect participants - diagnosis of diabetes mellitus (Type I or Type II).

Module 2:

  • Receipt of any non-investigational anticancer agents, including non-biologic agents and/or biologic agents or receipt of non-CNS or CNS radiation therapy.
  • Participants for whom treatment with posaconazole is per the local prescribing information.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
85 participants (estimated)

Study arms

  • Experimental
    Module 1: AZD3632 dose 1

    Participants will receive AZD3632 (dose 1) through the treatment period.

    Drug: AZD3632

  • Experimental
    Module 1: AZD3632 dose 2

    Participants will receive AZD3632 (dose 2) through the treatment period.

    Drug: AZD3632

  • Experimental
    Module 1: AZD3632 dose 3

    Participants will receive AZD3632 (dose 3) through the treatment period.

    Drug: AZD3632

  • Experimental
    Module 1: AZD3632 dose 4

    Participants will receive AZD3632 (dose 4) through the treatment period.

    Drug: AZD3632

  • Experimental
    Module 1: AZD3632 dose 5

    Participants will receive AZD3632 (dose 5) through the treatment period.

    Drug: AZD3632

  • Experimental
    Module 1: AZD3632 dose 6

    Participants will receive AZD3632 (dose 6) through the treatment period.

    Drug: AZD3632

  • Experimental
    Module 2: AZD3632 + posaconazole

    Participants will receive AZD3632 alone, then will receive AZD3632 in combination with posaconazole through treatment period.

    Drug: AZD3632 · Drug: Posaconazole

Interventions

  • DrugAZD3632

    AZD3632 will be administered orally.

  • Posaconazole will be administered orally.

06

What researchers measure

Primary outcomes

  1. Module 1: Number of participants with dose-limiting toxicity (DLT)

    Safety and tolerability of AZD3632 monotherapy in participants with advanced haematologic malignancies will be assessed.

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

  2. Module 1 and Module 2: Number of participants with dose modification, delay and discontinuations due to adverse events (AEs)

    Safety and tolerability of AZD3632 monotherapy in participants with advanced haematologic malignancies will be assessed.

    Time frame: Up to 3 years 1 month

  3. Module 1 and Module 2: Number of participants with treatment-emergent adverse events (TEAEs), treatment-related AEs (TRAEs) and serious adverse vents (SAEs)

    Safety and tolerability of AZD3632 monotherapy in participants with advanced haematologic malignancies will be assessed. Adverse events will be defined as treatment-emergent if they have an onset or worsen (by investigator report of a change in intensity) during the study treatment or the safety follow-up period but prior to any subsequent cancer therapy.

    Time frame: Up to 30 days after last dose (approximately 3 years 1 month)

Secondary outcomes

  1. Module 1 and Module 2: Maximum concentration (Cmax) of AZD3632

    The PK of AZD3632 as monotherapy (module 1) and in combination with posaconazole (module 2) will be assessed.

    Time frame: From Day 1 to 3 years 1 month

  2. Module 1 and Module 2: Time of maximum concentration (Tmax) of AZD3632

    The PK of AZD3632 as monotherapy (module 1) and in combination with posaconazole (module 2) will be assessed.

    Time frame: From Day 1 to 3 years 1 month

  3. Module 1: Trough concentration (Ctrough) of AZD3632

    The PK of AZD3632 as monotherapy will be assessed.

    Time frame: From Day 1 to 3 years 1 month

  4. Module 1: Area under the plasma concentration-time Curve from Time Zero to Infinity (AUC[inf]) of AZD3632

    The PK of AZD3632 as monotherapy will be assessed.

    Time frame: From Day 1 to 3 years 1 month

  5. Module 1 and Module 2: Area under the curve from time 0 to the time of last measurable concentration (AUC[0-t]) of AZD3632

    The PK of AZD3632 as monotherapy (module 1) and in combination with posaconazole (module 2) will be assessed.

    Time frame: From Day 1 to 3 years 1 month

  6. Module 1: Area under concentration-time curve in the dosing interval (AUCtau) of AZD3632

    The PK of AZD3632 as monotherapy will be assessed.

    Time frame: From Day 1 to 3 years 1 month

  7. Module 1: Apparent total body clearance (CL/F) of AZD3632

    The PK of AZD3632 as monotherapy will be assessed.

    Time frame: From Day 1 to 3 years 1 month

  8. Module 1: Apparent volume of distribution based on the terminal phase (VZ/F) of AZD3632

    The PK of AZD3632 as monotherapy will be assessed.

    Time frame: From Day 1 to 3 years 1 month

  9. Module 1: Half-life (t1/2) of AZD3632

    The PK of AZD3632 as monotherapy will be assessed.

    Time frame: From Day 1 to 3 years 1 month

  10. Module 1: Maximum concentration (Cmax) of AZD3632 (food effect)

    The preliminary effect of food on plasma PK of AZD3632 (conducted in a nested evaluation during backfills) will be assessed.

    Time frame: From Day 1 to 3 years 1 month

  11. Module 1: Time of maximum concentration (Tmax) of AZD3632 (food effect)

    The preliminary effect of food on plasma PK of AZD3632 (conducted in a nested evaluation during backfills) will be assessed.

    Time frame: From Day 1 to 3 years 1 month

  12. Module 1 and Module 2: Area under the curve from time 0 to the time of last measurable concentration (AUC[0-t]) of AZD3632 (food effect)

    The preliminary effect of food on plasma PK of AZD3632 (conducted in a nested evaluation during backfills) will be assessed.

    Time frame: From Day 1 to 3 years 1 month

  13. Module 1: Area under concentration-time curve in the dosing interval (AUCtau) of AZD3632 (food effect)

    The preliminary effect of food on plasma PK of AZD3632 (conducted in a nested evaluation during backfills) will be assessed.

    Time frame: From Day 1 to 3 years 1 month

  14. Module 1: Minimum concentration (Cmin) of AZD3632 (food effect)

    The preliminary effect of food on plasma PK of AZD3632 (conducted in a nested evaluation during backfills) will be assessed.

    Time frame: From Day 1 to 3 years 1 month

  15. Module 1: Ratio of Cmax between fed and fasted state

    The preliminary effect of food on plasma PK of AZD3632 (conducted in a nested evaluation during backfills) will be assessed.

    Time frame: From Day 1 to 3 years 1 month

  16. Module 1: Ratio of AUC(0-t) between fed and fasted state

    The preliminary effect of food on plasma PK of AZD3632 (conducted in a nested evaluation during backfills) will be assessed.

    Time frame: From Day 1 to 3 years 1 month

  17. Module 1: Ratio of AUCtau between fed and fasted state

    The preliminary effect of food on plasma PK of AZD3632 (conducted in a nested evaluation during backfills) will be assessed.

    Time frame: From Day 1 to 3 years 1 month

  18. Module 2: Plasma geometric mean ratio of Cmax

    The PK pf AZD3632 when co-administered with posaconazole will be assessed.

    Time frame: From Day 1 to 3 years 1 month

  19. Module 2: Plasma geometric mean ratio of AUC

    The PK pf AZD3632 when co-administered with posaconazole will be assessed.

    Time frame: From Day 1 to 3 years 1 month

  20. Module 2: Plasma concentration of posaconazole

    The PK pf AZD3632 when co-administered with posaconazole will be assessed.

    Time frame: From Day 1 to 3 years 1 month

  21. Module 1 and Module 2: Complete response rate (CR + CRh)

    Complete response rate is defined as the percentage of participants who have a complete remission (CR) or complete remission with partial haematological recovery (CRh) as assessed by the investigator at local site.

    Time frame: Up to 3 years 1 month

  22. Module 1 and Module 2: Time to response (TTR)

    TTR in participants with acute leukaemia is defined as the time from date of first dose until date of first documented complete response (CR/CRh) among participants with acute leukaemia in the Response Evaluable Set who achieved complete response as assessed by investigator at local site. TTR in participants with MDS is defined as the time from date of first dose until date of first documented objective response a CR (or CR equivalent), complete response with limited count recovery \[CRL\], CRh, partial response \[PR\], or haematologic improvement \[HI\]) among participants with MDS in the Response Evaluable Set who achieved objective response as assessed by investigator at local site.

    Time frame: Up to 3 years 1 month

  23. Module 1 and Module 2: Duration of response (DoR)

    DoR in participants with acute leukaemia is defined as the time from date of first documented complete response (CR/CRh) until date of first documented relapse or death (by any cause in the absence of relapse) as assessed by investigator at local site. DoR in participants with MDS is defined as the time from date of first documented objective response CR (or CR equivalent), CRL, CRh, PR, or HI until date of first documented relapse or death (by any cause in the absence of relapse) as assessed by investigator at local site.

    Time frame: Up to 3 years 1 month

  24. Module 1 and Module 2: Transfusion Independence (TI)

    TI is defined as no RBC and no platelet transfusion during any consecutive period of at least 56 days post-baseline after starting treatment with AZD3632 or cessation of treatment with AZD3632 but prior to start of subsequent new therapy.

    Time frame: Up to 3 years 1 month

  25. Module 1 and Module 2: Event-free Survival (EFS)

    EFS for participants with acute leukaemia is defined as the time from date of first dose until date of relapse, progressive disease, failure to achieve at least Morphologic leukaemia-free state (MLFS) by end of Cycle 6, or death due to any cause as assessed by investigator at a local site. EFS for participants with MDS is defined as the time from date of first dose until date of relapse, progressive disease, failure to achieve at least HI by end of Cycle 6, or death due to any cause.

    Time frame: From Cycle 2 Day 1 (each cycle is 28 days) up to disease follow-up (approximately 3 years 1 month)

  26. Module 1 and Module 2: Overall Survival (OS)

    OS is defined as the time from date of first dose until date of death due to any cause regardless of whether the participant withdraws from study therapy or receives another anticancer therapy.

    Time frame: From Cycle 2 Day 1 (each cycle is 28 days) up to disease follow-up (approximately 3 years 1 month)

  27. Module 1 and Module 2: Percentage of participants who receive subsequent allogeneic hematopoietic stem cell transplant (HSCT)

    Percentage of participants with acute leukaemia and MDS who receive subsequent allogeneic HSCT will be reported.

    Time frame: Up to 3 years 1 month

  28. Module 1 and Module 2: Overall Response Rate (ORR)

    ORR in participants with myelodysplastic syndromes (MDS) is defined as the percentage of participants who have a CR (or CR equivalent), CRL, CRh, PR, or HI as determined by investigator at a local site.

    Time frame: Up to 3 years 1 month

  29. Module 1 and Module 2: Time to Progression to acute myeloid leukaemia (AML)

    Time to progression to AML is defined from the time of first dose of AZD3632 until first diagnosis of AML, regardless of discontinuation of treatment or receiving of subsequent therapy.

    Time frame: Up to 3 years 1 month

07

Study locations

20 of 30 sites recruiting
  • Research Site
    Decatur, Illinois 62526, United States
    Recruiting
  • Research Site
    New York, New York 10065, United States
    Not yet recruiting
  • Research Site
    Chapel Hill, North Carolina 27599, United States
    Not yet recruiting
  • Research Site
    Durham, North Carolina 27705, United States
    Recruiting
  • Research Site
    Portland, Oregon 97239, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Houston, Texas 77030, United States
    Recruiting
  • Research Site
    Fitzroy, 3065, Australia
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Perth, WA 6000, Australia
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Toronto, Ontario M5G 2M9, Canada
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Montreal, Quebec H3T 1E2, Canada
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Copenhagen, 2100, Denmark
    Recruiting
  • Research Site
    Dresden, 01307, Germany
    Recruiting
  • Research Site
    Frankfurt A. Main, 60590, Germany
    Recruiting
  • Research Site
    Halle, 06097, Germany
    Recruiting
  • Research Site
    Heidelberg, 69120, Germany
    Recruiting
  • Research Site
    München, 81377, Germany
    Recruiting
  • Research Site
    Ulm, 89081, Germany
    Recruiting
  • Research Site
    Bologna, 40138, Italy
    Recruiting
  • Research Site
    Ravenna, 48121, Italy
    Recruiting
  • Research Site
    Bunkyō City, 113-8677, Japan
    Recruiting
  • Research Site
    Kashiwa, 277-8577, Japan
    Not yet recruiting
  • Research Site
    Okayama, 700-8558, Japan
    Recruiting
  • Research Site
    Seoul, 06351, South Korea
    Recruiting
  • Research Site
    Seoul, 06591, South Korea
    Recruiting
  • Research Site
    Seoul, 110-744, South Korea
    Recruiting
  • Research Site
    Edinburgh, EH4 2XU, United Kingdom
    Recruiting
  • Research Site
    London, EC1A 7BE, United Kingdom
    Not yet recruiting
  • Research Site
    London, SE5 9RS, United Kingdom
    Recruiting
  • Research Site
    Manchester, M20 4BX, United Kingdom
    Recruiting
  • Research Site
    Newcastle, NE7 7DN, United Kingdom
    Suspended

    Not enrolling at this site — choose another above.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portalVivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitment a made to the EFPIA PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Feb 2029, 37 months after the start.

Of 114 phase 1/2 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 56 and three quarters within 119. This study's planned 37 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2025
First posted
Sep 4, 2025
StartActual
Jan 9, 2026
Primary completionEst.
Feb 15, 2029
CompletionEst.
Feb 15, 2029
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Research Site is now Not yet recruiting
Oct 23, 2026
Enrollment
84→85
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Research Site is now Not yet recruiting
    Enrollment 84→85
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07155226
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 4, 2025
Start date
Jan 9, 2026
Primary completion
Feb 15, 2029 (estimated)
Completion
Feb 15, 2029 (estimated)
Last update
Oct 23, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion